CA
NZ
UK
AU
IND
US
● Third-quarter adjustedEarningswere $26.93 per share.
● Third-quarter adjustedOperating Incomewas $558 million, or $8.49 per share.
● Third-quarterGAAPNet Incomewas $175.3 million, or $0.75 per share.
● December-quarter net sales are guided to $19.5 billion to $21.5 billion.
● Third-quarter results were scheduled for the open on November 10.
● FreeCash Flowwas $19.11 billion in the quarter.
Xilio Therapeutics, Inc. filed its quarterly report on Form 10-Q with the U.S. Securities and Exchange Commission on November 10, 2026, covering the fiscal quarter ended September 30, 2026.
Director Richard H. Fearon filed a Form 4 with the SEC on November 10, 2026, disclosing a purchase of 6,000 ordinary shares of CRH Public Ltd Co on November 6, 2026.
Key HighlightsMicrovast Holdings (NASDAQ:MVST) was indicated at USD 0.3139 pre-market on Tuesday, November 10, 2026, down 49.17% from a calculated prior close of USD 0.6175 after the third-quarter report.Third-quarterRevenuefell 62.8% to USD 45.8 million from USD 123.3 million, and the net loss widened to …
The outlook added to the disappointment. Fourth-quarter revenue guidance of USD 133 million to USD 136 million points to flat to 2% growth, below expectations, with adjusted EBITDA of USD 18 million to USD 23 million and positive free cash flow. For the full …
Please wait processing your request...